Third AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy

​Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians. 


Credit Designation Statement
AACR has designated this live activity for a maximum of 20.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by Wednesday, March 30, 2018. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website and via email. Your CME certificate will be sent to you via email after the completion of the activity.


Statement of Educational Need, Target Audience, and Learning Objectives
As stated by Blasberg and Piwnica-Worms in 2012, the field of molecular imaging (i.e., visualizing both normal and abnormal molecular and cellular processes in vivo using non-invasive imaging strategies) was named as such in the late-1990's. Although heavily rooted in molecular and cell biology, many of the advances in molecular imaging occurred independently of the large advances in molecular biology and genetics in the 1980s and early 1990s. The field of imaging is growing and evolving to benefit cancer research and treatment not only at the phenotypic, diagnostic, anatomical, and physiological levels, but also at the cellular/molecular level. Molecular imagers are able to visualize the molecular basis of the disease and treatment efficacy in vivo. To develop this field that is so closely intertwined with the benchwork of cancer research and the personalized treatment and monitoring of therapeutic efficacy at the bedside, Blasberg and Piwnica-Worms place incredible value on collaboration. They said that for both the molecular imaging and cancer research/treatment fields to flourish, there is a need for "radiologic scientists and clinical researchers to share a common conceptual framework, vocabulary, and approach to genomic and proteomic science."  Blasberg called for this in a similar review article in 2003 stating, "Continued success in the future depends on bringing the imaging disciplines closer together, as well as further involvement with our molecular and cell biology colleagues."

According to the 2015, 2016, and 2017 American Association for Cancer Research Cancer Progress Reports, since this conference was last held in 2015, four new imaging agents have been approved by the FDA. For example, in 2017, the FDA approved a new optical imaging agent called aminolevulinic acid hydrochloride that helps visualize gliomas for more effective and accurate surgical removal. As technological advances in molecular imaging bring sensitivity and resolution to the molecular and cellular levels, it is becoming increasingly critical for imagers to better understand the needs of the cancer research and treatment community to not only optimize technologies, but also to translate these advances into clinical applications, diagnostics, efficacy measures in vivo, and drug delivery. Reciprocally, it is critical for cancer researchers and physicians to learn from imaging scientists about the power behind emerging technologies and how these technologies can better inform cancer research, clinical trial design, less invasive and earlier diagnosis, and treatment options.

After participating in this CME activity, physicians should be able to:

  1. Identify emerging technologies in molecular imaging of cancer, as well as identify innovative cancer therapies guided by molecular imaging in cancer treatment.

  2. Review the role of imaging in immunology and immunotherapy in monitoring therapeutic response, visualizing the microenvironment, and the uses of PET and MR in cell trafficking.

  3. Articulate advances in early detection of cancer due to new technologies and imaging.

  4. Identify how molecular imaging is being used in visualizing cellular interactions, metastasis, and metabolism of the cancer cell.

  5. Identify how imaging and optics are being utilized in guiding surgery.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgment of Financial or Other Support
This activity is supported by professional educational grants from Lilly. Any others will be disclosed at the activity.

Questions about CME?
Please contact the Office of CME at (215) 440-9300 or